Slate Medicines is a clinical-stage biotech developing next-generation therapeutics for migraine and other headache disorders, targeting PACAP/VIP biology to go beyond current CGRP-based treatments. Its lead asset, SLTE-1009, is a subcutaneously administered anti-PACAP/VIP monoclonal antibody aimed at better preventing migraines than existing standards of care.